Revvity (RVTY) cash flow statement

Health Care Equipment · NYSE · Health Care

$147.79 -0.71% Close Nov 17, 2026 Live

TrendArc score 44 of 100 · Health 5.7 · Momentum 7.1 · Moat 3.6 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 28, 2025

$509 million

down 6.0% from the year before

Revvity generated $509 million of free cash flow in the fiscal year to December 2025: $583 million of cash from operations less $74 million of capital spending. That was 17.8% of revenue, against 19.7% the year before. Over the last four quarters, to October 4, 2026, it was $603 million.

What stands out

  • Net share repurchases of $818 million and dividends of $33 million came to 167% of free cash flow in the fiscal year to December 2025.
  • It paid cash dividends in each of the last ten fiscal years.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 10 fiscal years

$500M$1.00B$1.50BJan 2017Dec 2017Dec 2018Dec 2019Jan 2021Jan 2022Jan 2023Dec 2023Dec 2024Dec 2025$319MFree cash flow $509MNet income $241M$500M$1.00B$1.50BDec 2017Dec 2019Jan 2022Dec 2023Dec 2025Free cash flow $509MNet income $241M

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to December 28, 2025

  1. Cash from operations 0.58
  2. Capital spending -0.07
  3. Free cash flow 0.51
  4. Net share repurchases -0.82
  5. Dividends -0.03
  6. Debt and other 0.10
  7. Net change in cash -0.24

In billions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 10 fiscal years

In billions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Oct 2026
Dec 2025Dec 2024Dec 2023Jan 2023Jan 2022Jan 2021Dec 2019Dec 2018Dec 2017Jan 2017
Operating activities
Net income0.240.270.690.570.940.730.230.240.290.23
Depreciation and amortisation0.410.430.430.430.310.200.210.180.100.10
Stock-based pay0.030.020.040.040.050.030.030.030.030.030.02
Working capital and other items-0.09-0.11-1.08-0.370.13-0.06-0.11-0.14-0.130.00
Cash from operations0.660.580.630.090.681.410.890.360.310.290.35
Investing activities
Capital spending-0.05-0.07-0.09-0.08-0.09-0.09-0.06-0.08-0.09-0.04-0.03
Businesses bought and sold, net0.000.000.000.01-3.98-0.41-0.40-0.06-1.53-0.05
Investments bought and sold, net0.000.70-0.68-0.04-0.02-0.02-0.01-0.010.030.00
Other investing0.060.162.07-0.02-0.02-0.01-0.010.000.270.00
Cash from investing-0.020.781.31-0.13-4.11-0.50-0.49-0.16-1.27-0.08
Financing activities
Debt issued or repaid, net0.00-0.72-0.52-0.563.07-0.190.21-0.070.820.06
Shares issued less bought back-0.26-0.82-0.36-0.38-0.07-0.050.030.01-0.030.01-0.14
Dividends paid-0.03-0.03-0.03-0.03-0.04-0.03-0.03-0.03-0.03-0.03-0.03
Other financing-0.01-0.01-0.010.00-0.05-0.01-0.04-0.05-0.020.00
Cash from financing-0.86-1.13-0.95-0.662.94-0.200.15-0.180.78-0.12
Exchange rate effect0.05-0.03-0.01-0.03-0.020.030.00-0.010.02-0.01
Net change in cash-0.240.250.44-0.150.220.210.03-0.04-0.170.14
Free cash flow
Free cash flow0.600.510.540.010.591.320.830.290.220.250.32
Free cash flow margin20.5%17.8%19.7%0.4%17.9%34.6%31.1%10.0%7.8%11.0%15.1%

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Revvity against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
ResMedRMD Jun 2026$1.65B29.2%
Idexx LaboratoriesIDXX Dec 2025$1.04B24.2%
DexcomDXCM Dec 2025$1.08B23.1%
RevvityRVTY Dec 2025$509M17.8%
SterisSTE Mar 2026$983M16.6%
InsuletPODD Dec 2025$350M12.9%
GE HealthCareGEHC Dec 2025$1.50B7.3%
Baxter InternationalBAX Dec 2025$323M2.9%
Peer median16.6%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Revvity with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Revvity from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.